Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IGF1R | P08069 | 5/20 | 0.51 |
| ▸ | TNK2 | Q07912 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 2/20 | 0.39 |
| ▸ | JAK2 | O60674 | 1/20 | 0.39 |
| ▸ | ATR | Q13535 | 2/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | NEK2 | P51955 | 2/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.36 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.36 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5082567 | 0.90 | IGF1R (0.44) | IGF1RTNK2HPGDJAK2POLB | |
| SCHEMBL5080636 | 0.82 | IGF1R (0.48) | IGF1RTNK2JAK2ATRPOLB | |
| SCHEMBL5084882 | 0.82 | IGF1R (0.48) | IGF1RTNK2CYP3A4NPC1RAB9A | |
| SCHEMBL4073244 | 0.81 | IGF1R (0.51) | IGF1RTNK2NEK2CYP3A4 | |
| SCHEMBL5079162 | 0.80 | IGF1R (0.50) | IGF1RTNK2HPGDNEK2CYP3A4 | |
| SCHEMBL5086965 | 0.80 | IGF1R (0.43) | IGF1RTNK2HPGDPOLB | |
| SCHEMBL5086140 | 0.79 | TNK2 (0.45) | IGF1RTNK2HPGD | |
| SCHEMBL5083298 | 0.79 | IGF1R (0.40) | IGF1RTNK2ATRRAB9AADORA2A | |
| SCHEMBL399552 | 0.78 | IGF1R (0.81) | IGF1RTNK2NEK2CYP3A4 | |
| SCHEMBL5086076 | 0.78 | IGF1R (0.44) | IGF1RTNK2HPGDJAK2ADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1979002-A2 | COMBINATION OF IGFR INHIBITOR AND ANTI-CANCER AGENT | OSI Pharmaceuticals, Inc. (US) | 2008-10-15 | — | — | EP | claimed |
| WO-2008076143-A1 | COMBINATION OF IGFR INHIBITOR AND ANTI-CANCER AGENT | OSI PHARMACEUTICALS, INC. (US) | 2008-06-26 | — | — | WO | claimed |
| WO-2007075554-A2 | COMBINATION OF IGFR INHIBITOR AND ANTI-CANCER AGENT | OSI PHARMACEUTICALS, INC. (US) | 2007-07-05 | — | — | WO | claimed |
| EP-2168968-A1 | 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitors | OSI Pharmaceuticals, Inc. (US) | 2010-03-31 | — | — | EP | disclosed |